Drug Updates

Drug updates provide the latest information and relevant warnings and notifications.

Update on Drugs & Devices: March-April 2021

The update covers: Cemiplimab-rwlc for IV injection - Libtayo® (Regeneron/Sanofi), HA-based dermal filler - Restylane® Defyne™ (Galderma), Tirbanibulin ointment 1% - Klisyri® (Almirall/Athenex), Anakinra for SC use - Kineret® (Swedish Orphan Biovitrum Sobi™), Immune modulatory vaccines for melanoma - IO102 and IO103 (IO Biotech).

2020 Index for Skin Therapy Letter – Dermatology Edition

This index covers all new skin treatments introduced in Skin Therapy Letter Dermatology Edition articles in 2020.

Update on Drugs & Devices: January-February 2021

The latest drug & device update covers: Orladeyo™ (BioCryst Pharmaceuticals), KPL-716 (Kiniksa Pharmaceuticals), Sklice® (Arbor Pharmaceuticals) and Picato® (Leo Pharma)

Update on Drugs & Devices: November – December 2020

This update covers: Gene therapy for DEB (AGLE-102), Golimumab for IV use (Simponi® Aria™), Clascoterone 1% cream (Winlevi®), Triplet melanoma therapy (Tecentriq® + Cotellic® and Zelboraf®), Ustekinumab for SC use (Stelara®), Calcipotriene + betamethasone dipropionate cream (Wynzora®), Abametapir 0.74% lotion (Xeglyze™), Sonidegib capsules (Odomzo®) and Halobetasol propionate + tazarotene lotion (Duobrii™).

Update on Drugs & Devices: September-October 2020

This update covers: Guselkumab SC use (Tremfya®), Adalimumab-fkjp SC use (Hulio®), Collagenase clostridium histolyticum-aaes SC use (Qwo™), Protein replacement therapy for XLHED (ER-004), Pembrolizumab IV use (Keytruda®), Minocycline 1.5% foam (Zilxi™), Microbiome-based non-aqueous ointment (ATR-12), Dupilumab SC use (Dupixent®) and Selumetinib capsules (Koselugo™)

Update on Drugs & Devices: May – June 2020

Update on Selumetinib capsules (Koselugo®), Crisaborole 2% ointment (Eucrisa®), Infliximab biosimilar for IV injection (Avsola™) and Baricitinib tablets (Olumiant®)

Update on Drugs & Devices: March – April 2020

This update covers Tazemetostat tablets/Tazverik™ (Epizyme, Inc.), Tazarotene lotion 0.045%/Arazlo™ (Ortho Dermatologics, Bausch Health) and Rituximab biosimilar for IV injection/ABP 798 (Amgen, Allergan).

Update on Drugs & Devices: January – February 2020

This update covers Lebrikizumab SC injection (Dermira), Infliximab-axxq for IV injection (Avsola™, Amgen), Trifarotene cream 50 mcg/g (Aklief®, Galderma), Adalimumab-afzb for SC injection (Abrilada™, Pfizer), Lidocaine + tetracaine (7%/7%) local anesthetic cream (Pliaglis®, Crescita Therapeutics), Maralixibat oral solution (Mirum Pharmaceuticals), Cetirizine hydrochloride for IV injection (Quzyttir™, TerSera Therapeutics) and Minocycline foam 4% (Amzeeq™, Foamix)

Update on Drugs & Devices: November – December 2019

The latest drug & device update covers: Trifarotene 0.005% cream (Aklief®, Galderma), Afamelanotide implant (Scenesse®, Clinuvel Pharmaceuticals), Rituximab for IV use (Rituxan®, Genentech), Jynneos™ (Bavarian Nordic), Aczone® (Almirall) and Juvéderm Voluma® XC (Allergan)

Update on Drugs & Devices: September – October 2019

The latest drug & device update covers: Adalimumab-bwwd for SC injection (Hadlima™), Apremilast tablets (Otezla®), Calcipotriene + betamethasone dipropionate (Enstilar® foam Taclonex® topical suspension), Bempegaldesleukin + nivolumab for IV use (NKTR-214 + Opdivo®), Dupilumab for SC injection (Dupixent®), Magnetic muscle stimulation for body contouring (CoolTone™), Laser device for body contouring (eon™ FR).

Update on Drugs & Devices: July – August 2019

Latest drug update covers Belimumab for IV use (Benlysta, GSK), Etanercept-ykro (Eticovo®, Samsung Bioepis), Halobetasol propionate 0.01% + tazarotene 0.045% lotion (Duobrii™, Bausch Health), Protein replacement therapy for SC injection (PTR-01, Phoenix Tissue Repair), Risankizumab for SC injection (Skyrizi™, AbbVie), Ruxolitinib tablets (Jakafi®, Incyte Corporatio), and Oral MEK inhibitor (PD-0325901, SpringWorks Therapeutics).

Update on Drugs & Devices: May – June 2019

Latest drug update covers Pembrolizumab for IV injection (Keytruda®, Merck & Co.), Guselkumab for SC injection (Tremfya®, MorphoSys/Janssen), Dupilumub for SC injection (Dupixent®, Regeneron), and Risankizumab for SC injection (Skyrizi™, AbbVie).

Update on Drugs & Devices: March – April 2019

Latest drug update covers Pembrolizumab, Oral JAK + SYK dual inhibitor, Lidocaine 7% + tetracaine 7% local anesthetic cream and PrabotulinumtoxinA-xvfs.

Update on Drugs & Devices: January – February 2019

Update on Dalbavancin hydrochloride for IV infusion (Xydalba™), Omadacycline for IV and oral use (Nuzyra™), Tildrakizumab-asmn for SC injection (Ilumya™), Adalimumab-adaz for SC injection (Hyrimoz™) and other new drugs and treatments.

Update on Drugs & Devices: November – December 2018

Update on PrabotulinumtoxinA, Tretinoin 0.05% lotion, Cemiplimab-rwlc, Autologous fibroblast gene therapy, Oral JAK3 inhibitor, Halobetasol propionate 0.01% lotion, Sarecycline hydrochloride tablets and HPV 9-valent vaccine.

Update on Drugs & Devices: September – October 2018

Updates on Binimetinib + Encorafenib (Mektovi® + Braftovi®), Crisaborole 2% ointment (Eucrisa™), Glycopyrronium tosylate 2.4% cloth (Qbrexza™), Secukinumab for SC injection (Consentyx®), Tecovirimat capsule (Tpoxx), Diacerein 1% ointment (CCP-020), Migalastat capsule (Galafold™), Mogamulizumabkpkc for IV use (Poteligeo®)

Update on Drugs & Devices: July – August 2018

Update on Dabrafenib + trametinib in combination (Tafinlar®+Mekinist®), Certolizumab pegol for SC injection (Cimzia®), Ubidecarenone injectable nanosuspension (BPM 31510), Diacerein 1% ointment (CCP-020), Ixekizumab for SC injection (Taltz®), Hyaluronic acid (HA) dermal filler (Restylane® Lyft®), and Rituximab for IV use (Rituxan®).

Update on Drugs & Devices: May-June 2018

Update on Drugs & Devices May and June 2018: Tildrakizumab-asmn for SC injection Ilumya™, Lidocaine topical system 1.8% for postherpetic neuralgia ZTlido™, Secukinumab for SC injection Cosentyx®, Vaginal gel for prevention of urogenital chlamydia Amphora®.

Skin Treatments Introduced in 2017

A look back at skin treatments introduced in 2017 for the following type/class of therapy: Antibiotic agents, anti-cancer agents, atopic dermatitis, dermal fillers, fabry disease, hereditary angioedema, herpes zoster, hidradenitis suppurativa, psoriasis, psoriatic arthritis, rosacea...

Update on Drugs and Drug News: March-April 2018

Update on Drugs & Devices March and April 2018: Hydrogen peroxide topical solution Eskata™, Mepolizumab for SC injection Nucala® GSK, Brentuximab vedotin for IV use Adcetris®, CoolSculpting®, (PDF) patch DeScribe® PFD Patch, Adhesive patch for melanoma detection Pigmented Lesions Assay (PLA)

Update on Drugs and Drug News: January-February 2018

Update on drugs includes Onabotulinum-toxinA for injection (Botox® Cosmetic), Hyaluronic acid dermal filler (Restylane® Silk), Ustekinumab for SC injection (Stelara®), Golimumab for IV infusion (RSimponi Aria®), Herpes zoster vaccine (non-live recombinant, AS01B adjuvanted) suspension for IM injection (Shingrix), Brentuximab vedotin for IV infusion (Adcetris®)

Update on Drugs and Drug News: November-December 2017

November-December 2017 Update on drugs includes Adalimumab-adbm for SC injection Cyltezo™, Adalimumab biosimilar Imraldi®, Cemiplimab REGN2810, Oral migalastat Galafold™, and Secnidazole oral granules Solosec™

Update on Drugs and Drug News: September-October 2017

September-October 2017 Update on drugs include Isopropyl myristate solution Resultz®, Delafloxacin oral and IV formulations Baxdela™, Plasma-derived concentrate of C1 esterase inhibitor SC (human) Haegarda®, Oral dimethyl fumarate Skilarence®, Abatacept for IV or SC injection Orencia®, Consentyx®, Tremfya™, Yervoy® and Benlysta®.

Update on Drugs and Drug News: July-August 2017

This drug update covers Infliximab-abda for IV infusion Renflexis®, Ozenoxacin 1% cream Ozanex™, Standardized allergen extract of house dust mites sublingual tablet Acarizax®, Doxycycline hyclate immediate release tablet, and UVB Phototherapy SystemClarify™ Home Light Therapy System.

Update on Drugs and Drug News: May-June 2017

Update on Dupilumab for SC injection Dupixent®, Dupilumab for SC injection, Avelumab for IV injection Bavencio®, Hyaluronic acidbased injectable dermal filler Juvéderm®, Biosimilar to adalimumab for SC injection Amgevita™ Vollure™ XC, Adalimumab for SC injection Humira®, and Amgevita™.

Update on Drugs and Drug News: March-April 2017

Drug update on Oxymetazoline hydrochloride 1% cream Rhofade™, Brodalumab for SC injection Siliq™, Cryolipolysis for upper arm fat reduction CoolAdvantage™, Petite applicator for CoolSculpting® Zeltiq®, Wound healing device WoundShiel™

Skin Treatments Introduced in 2016

The list covers new skin treatments for Actinic Keratosis, Hemangioma, Hidradenitis Suppurativa, as well as Anti-acne Agents, Antibacterial Agents, Anti-cancer Agents, Dermal Fillers, Neuromodulator and other treatments and drugs.

Update on Drugs and Drug News: January-February 2017

Update on drugs, approval dates, and comments for Nivolumab + ipilimumab (Opdivo® + Yervoy®), Etanercept for SC injection (Enbre®), Crisaborole 2% ointment (Eucrisa™ ), Hyaluronic acid dermal fillers Restylane® (Refyne Restylane® Defyne).

Update on Drugs and Drug News: November-December 2016

Update on drugs, approval dates, and comments. Brodalumab for SC injection (Lumicef®), Etanercept-szzs for SC injection (Amjevita™), Propranolol hydrochloride oral solution 3.75 mg/ml (Hemangiol®), Calcipotriol 50 mcg/g + betamethasone dipropionate 0.5 mg/g foam (Enstilar®) are covered.

Update on Drugs and Drug News: September-October 2016

This update covers Pembrolizumab IV injection (Keytruda®), Hyaluronic acid gel filler (Juvéderm Volbella® XC), Biosimilar of infliximab (Flixabi®), Ceftaroline fosamil for IV infusion (Teflaro®), Dermal filler with calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse® + Lidocaine), Ixekizumab SC injection (Talz®), Adapalene gel 0.1% (Differin® Gel), C1 esterase inhibitor(human) for IV infusion (Berinert®)

Update on Drugs and Drug News: July-August 2016

Update on Bilastine tablet (Blexten™), Ixekizumab SC injection (Talz®), Wound care gel (Lasercyn™ gel), Ceftaroline fosamil (Teflaro®), Nivolumab + ipilimumab (Opdivo® + Yervoy®), PDT for actinic keratosis (Ameluz® gel + BF-RhodoLED®)

Update on Drugs and Drug News: May-June 2016

Update on Betamethasone dipropionate 0.05% spray (Sernivo™), Dapsone 7.5% gel (Aczone®), Cobimetinib + vemurafenib (Cotellic™ + Zelboraf®), Botulinum toxin type A for injection (Bocouture®), Calcipotriol + betamethasone dipropionate foam (Enstilar®), (Talz®), (Inflectra™), (Pruridexin™), and (Dermadexin™)

Update on Drugs and Drug News: March-April 2016

Update on (Beteflam™), Human papillomavirus (HPV) 9-valent vaccine, recombinant (Gardasil®9), (Imlygic®), Pembrolizumab IV injection (Keytruda®), Adalimumab SC injection (Humira®), Secukinumab SC injection (Cosentyx®), Ustekinumab SC injection (Stelara®), and Nivolumab + ipilimumab (Opdivo® + Yervoy®).

Update on Drugs and Drug News: January-February 2016

January and February 2016: Update on drugs, approval dates, and comments. Autologous cell suspension (ReCell® ReGenerCell® ReNovaCell®), Calcipotriene 0.005% + betamethasone dipropionate 0.064% foam (Enstilar®), Ipilimumab (Yervoy®), Talimogene laherparepvec (T-Vec) oncolytic virus therapy (Imlygic™), Cobimetinib + vemurafenib (Cotellic™ + Zelboraf®), Dabrafenib + trametinib (Tafinlar® + Mekinist®), Nivolumab injection (Opdivo®) are covered.

Update on Drugs and Drug News: November-December 2015

Update on Polidocanol 1% injectable foam (Varithena®), Cobimetinib + vemurafenib (Cotellic™ + Zelboraf®), Adalimumab SC injection (Humira®), Hyaluronic acid filler (Juvederm® Ultra XC), Nivolumab + ipilimumab (Opdivo® + Yervoy®), Ingenol mebutate gel (Picato®)

Update on Drugs and Drug News: September-October 2015

Update on Nivolumab IV infusion (Opdivo®), Pembrolizumab IV infusion (Keytruda®), Sonidegib phosphate capsules (Odomzo®), Azelaic acid 15% foam (Finacea® Foam), Adapalene 0.3% + benzoyl peroxide 2.5% gel (Epiduo® Forte), Deoxycholic acid injection (Belkyra™), Hyaluronic acid gel injectable dermal filler (Restylane® Lyft with Lidocaine), Dermal filler with calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse® (+)

Update on Drugs and Drug News: July-August 2015

Update on Deoxycholic acid injection (Kybella™), Ivermectin 1% cream (Rosiver®), Adalimumab SC injection (Humira®), Apremilast tablets (Otezla®), and Dermal filler with calcium hydroxylapatite (CaHA) (Radiesse®)

Update on Drugs and Drug News: May-June 2015

Update on Varicose vein n-butyl-2-cyanoacrylate adhesive polymer (VenaSeal™ Closure System), Dermal filler + calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse®), Dalbavancin for IV injection (Xydalba™), Pembrolizumab for IV infusion (Keytruda®)

Update on Drugs and Drug News: March-April 2015

Update on Human papillomavirus 9-valent vaccine, recombinant (Gardasil®9), Ivermectin 1% cream (Soolantra®), Naftifine HCl 2% gel & cream (Naftin®), Nivolumab IV infusion (Opdivo®), Polymethylmethacrylate collagen dermal filler for acne scars (Bellafill®), Secukinumab SC injection (Consentyx™).

Update on Drugs and Drug News: January-February 2015

Update on Apremilast tablets (Otezla®), Collagenase clostridium histolyticum for injection (Xiaflex®), Afamelanotide 16 mg subcutaneous bioresorbable implants (Scenesse®), Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Dupilumab SC injection, Apremilast tablets (Otezla®).

POPULAR